The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
C-reactive protein (CRP) is an acute-phase protein that is produced in large amounts by hepatocytes, upon stimulation by the cytokines interleukin-6, tumor-necrosis-factor-alpha and interleukin-1beta, during an acute-phase response. CRP is an objective marker of inflammation and, in gastrointestinal diseases such as Crohn's disease and acute pancreatitis, its levels correlate well with clinical disease activity. In contrast to its use as a marker in Crohn's disease, however, CRP is a less reliable marker of inflammation and disease activity in patients with ulcerative colitis, except perhaps for severe, extensive colitis. The increased production of CRP after an acute-phase stimulus, such as active gut inflammation, might explain why strong anti-inflammatory agents, such as anti-tumor-necrosis-factor-alpha antibodies and other biologic agents, work particularly well in patients with increased levels of CRP. CRP is also useful as a laboratory marker to predict prognosis and relapse in patients with Crohn's disease and acute pancreatitis. Elevated CRP levels have been associated with an increased risk of colorectal cancer and are a marker of poor prognosis, indicating more advanced disease and, possibly, reduced survival. An important question that remains is how often CRP levels should be measured. Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot repla…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CRP level is often used in chronic inflammatory diseases as a marker of active inflammation; it is typically understood to be an acute phase reactant 19 .”
From The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity (2009) · cites this paper as [19]
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953 · cited 1×
“68), it was less strong as a risk factor compared with well-established risk factors, such as increased cholesterol and cigarette smoking”
BackgroundInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752 · cited 1×
“The anti-TNFα antibodies are very efficacious in patients with Crohn's disease”
BackgroundSelf-citationThe Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226 · cited 1×
“The anti-TNFα antibodies are very efficacious in patients with Crohn's disease”
BackgroundSelf-citationTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundA Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundPredicting outcome in severe ulcerative colitis.
Travis, S. P., Farrant, J. M., Ricketts, C., Nolan, D. J., Mortensen, N. M., Kettlewell, M. G., & Jewell, D. P. (1996) · Gut · doi:10.1136/gut.38.6.905 · Cited by 788
Vigushin, D. M., Pepys, M. B., & Hawkins, P. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116336 · Cited by 636 · cited 1×
“infection, inflammation, trauma, childbirth, severe burns, stress and neoplasia), however, the liver has a large capacity to increase the baseline production of CRP by upregulating its transcription in hepatocytes”
BackgroundSolem, C. A., Loftus, E. V., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000173271.18319.53 · Cited by 587
C-Reactive Protein and the Risk of Incident Colorectal Cancer
Erlinger, T. P. (2004) · JAMA · doi:10.1001/jama.291.5.585 · Cited by 533 · cited 1×
“In a prospective, nested, case-control study of 22,887 adult residents of Washington County, Maryland, USA, who were followed between 1989 and 2000”
BackgroundSystemic inflammatory response predicts survival following curative resection of colorectal cancer
McMillan, D. C., Canna, K., & McArdle, C. S. (2003) · British Journal of Surgery · doi:10.1002/bjs.4038 · Cited by 454 · cited 1×
“Patients with increased preoperative CRP levels more often have more advanced disease (larger tumor size, advanced DUKES' STAGE with liver metastases, peritonitis carcinomatosa, lymph-node metastasis, intravascular invasion) compared with patients with normal CRP levels”
BackgroundDervenis, C., Johnson, C. D., Bassi, C., Bradley, E., Imrie, C. W., McMahon, M. J., & Modlin, I. (1999) · International journal of pancreatology · doi:10.1007/bf02925968 · Cited by 451
Wilson, C., Heads, A., Shenkin, A., & Imrie, C. W. (1989) · Journal of British Surgery · doi:10.1002/bjs.1800760224 · Cited by 319
Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis
FAGAN, E. A., DYCK, R. F., MATON, P. N., HODGSON, H. J. F., CHADWICK, V. S., PETRIE, A., & PEPYS, M. B. (1982) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1982.tb02244.x · Cited by 311 · cited 1×
“This correlation is observed for both Crohn's disease as well as for ulcerative colitis, but is much stronger for Crohn's disease”
BackgroundC-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
Bataille, R., Boccadoro, M., Klein, B., Durie, B., & Pileri, A. (1992) · Blood · doi:10.1182/blood.v80.3.733.733 · Cited by 294
Evidence for continuous stimulation of interleukin-6 production in Crohn's disease
Gross, V., Andus, T., Caesar, I., Roth, M., & Schölmerich, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90098-j · Cited by 293
Louis, E. J., Vermeire, S. A. R. A., Rutgeerts, P., Vos, M. D., Gossum, A. V., Pescatore, P., Fiasse, R., Pelckmans, P. A., Reynaert, H., D’Haens, G., et al. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/713786515 · Cited by 270
Self-citationNozoe, T., Matsumata, T., Kitamura, M., & Sugimachi, K. (1998) · The American Journal of Surgery · doi:10.1016/s0002-9610(98)00204-9 · Cited by 223 · cited 1×
“Patients with increased preoperative CRP levels more often have more advanced disease (larger tumor size, advanced DUKES' STAGE with liver metastases, peritonitis carcinomatosa, lymph-node metastasis, intravascular invasion) compared with patients with normal CRP levels”
BackgroundC-reactive protein, inflammation, and coronary risk
Ridker, P. M., & Morrow, D. A. (2003) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00079-1 · Cited by 187 · cited 1×
“Probably the best known is the use of CRP to predict the risk of cardiovascular disease and poor outcome after myocardial infarction”
BackgroundPuolakkainen, P., Valtonen, V, Paananen, A., & Schröder, T. (1987) · Gut · doi:10.1136/gut.28.6.764 · Cited by 180
Boirivant, M., Leoni, M., Tariciotti, D., Fais, S., Squarcia, O., & Pallone, F. (1988) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-198808000-00011 · Cited by 170
Gross, V., Sch�lmerich, J., Leser, H.-G., Salm, R., Lausen, M., R�ckauer, K., Sch�ffel, U., Lay, L., Heinisch, A., Farthmann, E. H., et al. (1990) · Digestive Diseases and Sciences · doi:10.1007/bf01537230 · Cited by 166
Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A.
Viedma, J. A., Pérez-Mateo, M., Domínguez, J. E., & Carballo, F. (1992) · Gut · doi:10.1136/gut.33.9.1264 · Cited by 164
A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease
Brignola, C., Campieri, M., Bazzocchi, G., Farruggia, P., Tragnone, A., & Lanfranchi, G. A. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90206-4 · Cited by 159
Tall, A. R. (2004) · New England Journal of Medicine · doi:10.1056/nejme048020 · Cited by 158 · cited 1×
“infection, inflammation, trauma, childbirth, severe burns, stress and neoplasia), however, the liver has a large capacity to increase the baseline production of CRP by upregulating its transcription in hepatocytes”
BackgroundSerum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications
Nikiteas, N. I. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i11.1639 · Cited by 156
Sandborn, W. J., Feagan, B. G., Radford-Smith, G., Kovacs, A., Enns, R., Innes, A., & Patel, J. (2004) · Gut · doi:10.1136/gut.2003.035253 · Cited by 152
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.
Andre, C., Descos, L., Landais, P., & Fermanian, J. (1981) · Gut · doi:10.1136/gut.22.7.571 · Cited by 140 · cited 1×
“Various authors have investigated CRP as part of a panel of inflammatory markers in IBD”
BackgroundDiffering acute phase responses in Crohn's disease and ulcerative colitis.
Saverymuttu, S. H., Hodgson, H. J., Chadwick, V. S., & Pepys, M. B. (1986) · Gut · doi:10.1136/gut.27.7.809 · Cited by 137 · cited 1×
“Whereas certain diseases such as Crohn's disease and rheumatoid arthritis are associated with a strong CRP response, other diseases such as systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, and ulcerative colitis are associated with only a modest or absent CRP response”
BackgroundBüchler, M. W., Malfertheiner, P., Schoetensack, C., Uhl, W. H., & Beger, H. G. (1986) · International Journal of Pancreatology · doi:10.1007/bf02795248 · Cited by 133
Useful Markers for Predicting Severity and Monitoring Progression of Acute Pancreatitis
Werner, J., Hartwig, W., Uhl, W. H., Müller, C., & Büchler, M. W. (2003) · Pancreatology · doi:10.1159/000070079 · Cited by 132
Poullis, A. P., Zar, S., Sundaram, K. K., Moodie, S. J., Risley, P., Theodossi, A., & Mendall, M. A. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200204000-00013 · Cited by 122
C-Reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders
Shine, B. S. F., Berghouse, L., Lennard‐Jones, J. E., & Landon, J. (1985) · Clinica Chimica Acta · doi:10.1016/0009-8981(85)90219-0 · Cited by 116 · cited 1×
“Diagnosis and differential diagnosis An early study from St Mark's Hospital, London, UK, investigated 82 adults who had been referred with abdominal symptoms”
BackgroundC-Reactive Protein Levels Are Not Associated with Increased Risk for Colorectal Cancer in Women
Zhang, S. M., Buring, J. E., Lee, I.-M., Cook, N. R., & Ridker, P. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00008 · Cited by 115
Indications for investigation of chronic gastrointestinal symptoms.
Beattie, R. M., Walker-Smith, J. A., & MURCH, S. H. (1995) · Archives of Disease in Childhood · doi:10.1136/adc.73.4.354 · Cited by 110 · cited 1×
“undertook a similar approach and studied 91 children (mean age 11 years) referred for symptoms of abdominal pain, diarrhea, rectal bleeding, weight loss or mouth ulceration”
MethodPaajanens, H., Laato, M. K., Jaakkola, M., Pulkki, K. J., Niinikoski, J., & NORDBACK, I. H. (1995) · British journal of surgery · doi:10.1002/bjs.1800820244 · Cited by 89
Update in inflammatory bowel disease pathogenesis
Rogler, G. (2004) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200407000-00003 · Cited by 75 · cited 1×
“The exact cause of IBD remains incompletely understood, but more and more evidence suggests that the gut flora triggers sustained inflammation in a genetically susceptible host”
BackgroundChung, Y.-C., & Chang, Y.-F. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200304000-00006 · Cited by 73 · cited 1×
“Patients with increased preoperative CRP levels more often have more advanced disease (larger tumor size, advanced DUKES' STAGE with liver metastases, peritonitis carcinomatosa, lymph-node metastasis, intravascular invasion) compared with patients with normal CRP levels”
BackgroundSearch for prognostic markers for acute pancreatitis
Windsor, J. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02317-5 · Cited by 67
Oezcueruemez-Porsch, M., Kunz, D., Hardt, P. D., Fadgyas, T., Kress, O., Schulz, H. ‐., Schnell‐Kretschmer, H., Temme, H., Westphal, S., Luley, C. H., et al. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018887704337 · Cited by 63 · cited 1×
“Predicting pancreatitis after endoscopic retrograde pancreatography Three prospective studies including a total of 221 patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) have investigated inflammatory markers to predict post-ERCP pancreatitis—results show that CRP is a good marker for the detect…”
BackgroundImmunological Studies in Inflammatory Bowel Disease
Pepys, M. B., Druguet, M., Klass, H., Dash, A. C., Mirjah, D. D., & Petrie, A. (1976) · Novartis Foundation symposium · doi:10.1002/9780470720288.ch14 · Cited by 53
Tromm, A., Tromm, C. D., Hüppe, D., Schwegler, U., Krieg, M., & May, B. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011182 · Cited by 43 · cited 1×
“Various authors have investigated CRP as part of a panel of inflammatory markers in IBD”
BackgroundSignificance of measurement of high-sensitivity C-reactive protein in acute pancreatitis
Imamura, T., Tanaka, S., Yoshida, H., Kitamura, K., Ikegami, A., Takahashi, A., Niikawa, J., & Mitamura, K. (2002) · Journal of Gastroenterology · doi:10.1007/s005350200157 · Cited by 42 · cited 1×
“Interestingly, a small study in 20 patients with acute pancreatitis showed that a high-sensitivity CRP assay (hs-CRP), which can detect minor elevations of CRP (of under 3 mg/l) could detect elevated levels of CRP in the early phase of acute pancreatitis and that hs-CRP assay would be a valuable investigation in patie…”
BackgroundSerum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis
Kaw, M., & Singh, S. (2001) · Gastrointestinal Endoscopy · doi:10.1067/mge.2001.117763 · Cited by 34 · cited 1×
“Predicting pancreatitis after endoscopic retrograde pancreatography Three prospective studies including a total of 221 patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) have investigated inflammatory markers to predict post-ERCP pancreatitis—results show that CRP is a good marker for the detect…”
BackgroundRicci, G., Ambrosi, A., Resca, D., Masotti, M., & Alvisi, V. (1995) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(96)82632-1 · Cited by 23
Biological markers of short term relapse in Crohn's disease (CD)
Consigny, Y., Modigliani, R., Colombel, J. F., Dupas, J. L., & Mary, J. (2001) · Gastroenterology · doi:10.1016/s0016-5085(08)80693-2 · Cited by 21
Kiviniemi, H., Juvonen, T. S., & Mäkelä, J. T. (1994) · HPB Surgery · doi:10.1155/1994/69467 · Cited by 7 · cited 1×
“Predicting pancreatitis after endoscopic retrograde pancreatography Three prospective studies including a total of 221 patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) have investigated inflammatory markers to predict post-ERCP pancreatitis—results show that CRP is a good marker for the detect…”
Hämäläinen, M. T., Grönroos, P., & Grönroos, J. (2002) · Scandinavian Journal of Surgery · doi:10.1177/145749690209100408 · Cited by 5
Safety of CDP870, a pegylated humanized anti-TNF antibody fragment, in Crohn?s disease
Schreiber, S. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)01513-2 · Cited by 3
Research works printed but not linked: 1
- Rutgeerts P et al. (2003) Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease [Abstract]. Gut 52 (Suppl): A239
Cited by
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Dignass, A., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Mantzaris, G., Reinisch, W., Colombel, J.-F., Vermeire, S., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.003 · Cited by 888
Self-citationStange, E. F., Travis, S. P. L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A., Feakins, R., Fléjou, J. F., Herfarth, H., Hommes, D. W., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.001 · Cited by 555
Self-citation
Metadata
- Authors
- Vermeire, S., Van Assche, G., & Rutgeerts, P.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Vermeire, Séverine
- ORCID
- Vermeire, Séverine
- Venue
- Nature Clinical Practice Gastroenterology & Hepatology
- Published
- 2005-12
- Volume
- 2
- Issue
- 12
- Pages
- 580-586
- ISSN
- 1743-4378 (ISSN-L)
- 1743-4386
- OpenAlex
- W2036630215
- Cited by
- 149
- References
- 51
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 9 · 2012: 6
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- C-reactive protein, inflammatory markers, gastrointestinal inflammation, Crohn's disease, ulcerative colitis, acute pancreatitis, disease activity monitoring, colorectal cancer risk, anti-TNF therapy, acute phase response, interleukin-6, TNF-α
- MeSH terms
- C-Reactive Protein, Gastrointestinal Diseases, Humans, Inflammation, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.